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MeCP2Epigenetics refers to the study of heritable changes in the pattern of gene expression that is controlled by a
mechanism speciﬁcally not due to changes the primary DNA sequence. Well-known epigenetic mechanisms
include DNA methylation, post-translational histone modiﬁcations and RNA-based mechanisms including
those controlled by small non-coding RNAs (miRNAs). Recent studies have shown that epigenetic modiﬁca-
tions orchestrate the hepatic stellate cell (HSC) activation and liver ﬁbrosis. In this review we focus on
the aberrant methylation of CpG island promoters of select genes is the prominent epigenetic mechanism
to effectively silence gene transcription facilitating HSC activation and liver ﬁbrosis. Furthermore, we also
discuss epigenetic dysregulation of tumor-suppressor miRNA genes by promoter DNA methylation and the
interaction of DNA methylation with miRNAs involved in the regulation of HSC activation and liver ﬁbrosis.
Recent advances in epigenetics alterations in the pathogenesis of liver ﬁbrosis and their possible use as
new therapeutic targets and biomarkers.
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Liver ﬁbrosis results from persistent liver jury, including viral
hepatitis, alcohol abuse, metabolic diseases, autoimmune diseases,
and cholestatic liver diseases [1]. During ﬁbrosis progression, inﬂam-
mation and liver injury trigger complex cellular events that result in
collagen deposition and the disruption of the normal liver architec-
ture [2]. Over the last two decades, sinusoidal resident hepatic stellate
cells (HSCs) have been commonly recognized as the major source of
extracellular matrix (ECM). In the normal liver, HSCs are quiescent,
vitamin A-storing adipogenic cells, However, following a ﬁbrogenic
stimulus, HSCs undergo a complex activation process associated
with morphological changes from a quiescent vitamin A-storing cell
to that of an activated myoﬁbroblast-like cell [3,4]. HSC activation is
also associated with a dramatic increase in the synthesis and deposi-
tion of ECM components, marked upregulation of α-smooth muscle
actin (α-SMA), collagen, tissue inhibitors of metalloproteinases
(TIMP1) and desmin, production of proﬁbrogenic cytokines/growth
factors such as transforming growth factor-β (TGF-β), platelet-derived
growth factor (PDGF) and ﬁbroblast growth factor (FGF), as well as
pro-inﬂammatory molecules including interleukin (IL)-6, intercellular
adhesion molecule-1 (ICAM-1) and monocyte chemotactic protein-1
(MCP-1) [5–7].
Because HSC activation and liver ﬁbrosis are orchestrated by the
same signals, for example by growth factors such as TGF-β, the
molecular mechanisms which exert global control of HSC activation
and liver ﬁbrosis incompletely understood. Recent works from our
group and from others implicated that epigenetic modiﬁcations play
an important role in determining HSC activation and liver ﬁbrosis
(Fig. 1). Here we review insights into the role of epigenetics in HSC
activation and liver ﬁbrosis.2. The pathogenesis of liver ﬁbrosis
Liver ﬁbrosis, irrespective of aetiology, is a dynamic and highly
integrated molecular, tissue and cellular process that leads to pro-
gressive accumulation of ECM components in an attempt to limit
hepatic damage in chronic liver diseases [8]. The terminal outcome
of liver ﬁbrosis is liver cirrhosis, a condition characterized by distor-
tion of the normal architecture, septae and nodule formation, altered
blood ﬂow, portal hypertension, hepatocellular carcinoma and ulti-
mately liver failure [9]. The hepatic stellate cell (HSC) is the main
ﬁbrogenic cell type orchestrating the deposition of ECM in the injured
liver and it also has been identiﬁed as a primary effector in liver
inﬂammation [4].
HSCs are resident perisinusoidal cells in the subendothelial space
between hepatocytes and sinusoidal endothelial cells [10]. These cells
are strategically positioned to intimately interact with hepatocytes,
endothelial cells, and nerve endings through their numerous processes
extending across the space of Disse [11]. Under pathological conditions,
including injury, inﬂammation, hepatitis B virus (HBV) or hepatitis C
virus (HCV) infection, quiescent HSC have been reported to undergo a
particular process of activation which involves signiﬁcant changes in
morphology and phenotypical responses observed in either human or
rat HSC when cultured on plastic substrate [12–14].
Several factors have been identiﬁed to promote HSC activation.
Damage to hepatocytes and Kupffer cell activation are still considered
the main effectors driving HSC activation [15,16]. Mediators released
from damaged hepatocytes, such as lipid peroxidation products,intermediate metabolites of drugs or hepatotoxins, acetaldehyde
and 1-hydroxyethyl radical from alcohol metabolism aswell as reactive
oxygen species (hydrogen peroxide, superoxide radical and others are
strong inducers of HSC activation [17].Once activated by bacterial
products, Kupffer cells secrete a large number of pro-inﬂammatory
and ﬁbrogenic mediators. Activation of HSC by macrophage-derived
TGF-β or insulin-like growth factor is an early feature of ﬁbrogenesis
which promotes a switch in HSC gene expression to initiate matrix
remodeling [18].
Advances of understanding gene regulation in HSCs has paralleled
the dramatic expansion of knowledge about both traditional mecha-
nisms of gene regulation, including transcription factor activity, local-
ization and modiﬁcation, as well as epigenetic regulation of gene
expression by DNA methylation, histone modiﬁcation and microRAN
interactions [19–24]. Elucidating the precise molecular mechanisms
underlying HSC activation and liver ﬁbrosis is translating into fruitful
new therapeutic approaches.
3. Overview of DNA methylation
The methylation of the C5 position of the cytosine base with
S-adenosyl methionine as the methyl donor is found in approximately
70–80% of CpG dinucleotides in somatic mammalian cells and to some
extent in non-CpG sequences in embryonic stem cells [25,26]. DNA
methylation is currently the most widely studied form of epigenetic
programming. The methylation of cytosine residues within CpG
sequences is catalysed by DNA methyltransferases (DNMTs) [27]. In
mammals, ﬁve members of the DNMT family have been identiﬁed:
DNMT1, DNMT2, DNMT3A, DNMT3B, and DNMT3L. Among these pro-
teins, only DNMT1, DNMT3A, and DNMT3B exhibit methyltransferase
activity.DNMT3a and DNMT3b target unmethylated CpGs and therefore
are termed de novo methyltransferases, while DNMT1 maintains DNA
methylation during replication by copying the methylation pattern of
the parent DNA strand onto the newly synthesized strand [28,29].
DNA methylation of the promoter regions is generally related to
transcriptional repression through different mechanisms, including
the inhibition of transcription factor binding and the recruitment
of methyl-CpG-binding domain (MBD) proteins and their associated
complexes [30]. So far, six methyl-CpG-binding proteins, including
MeCP2, MBD1, MBD2, MBD3, MBD4 and Kaiso, have been reported in
mammals [31]. MeCP2 is a member of a small family of methylated
DNA-binding domain proteins that was ﬁrst described through its afﬁn-
ity for DNA sequences containing methylated 5′-CpG-3′dinucleotides
[32]. The ability ofMeCP2 to bindmethylated DNA has been interpreted
in the context of transcriptional repression and silencing of speciﬁc
target genes.In addition, MeCP2 binds the corepressor mSin3A, which
is thought to recruit histone deacetylases, providing a mechanism for
the transcriptional repression of genes with methylated CpG sites
[33]. Interestingly, MeCP2 was shown to associate with the transcrip-
tional activator CREB1 at the promoter of somatostatin, a gene
upregulated in Mecp2 duplication mice, thereby suggesting a potential
activation mechanism [34].
4. Methylated genes in liver ﬁbrosis
Abnormal patterns of DNA methylation in liver ﬁbrosis have been
recognized over the last few years and so far a number of aberrantly
hypermethylated genes have been discovered. These genes have
been found to be hypermethylated either by direct examination of
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Fig. 1. Overview of the role of DNA methylation in pathobiology of liver ﬁbrosis.
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ment with demethylating agents such as 5-aza-2′-deoxycytidine
(5-azadC). Transcriptional repression of some genes has been
consistently shown to be due to promoters hypermethylation of
genes in activated HSC and liver ﬁbrosis. The role of these genes in
pathobiology of liver ﬁbrosis is reviewed in greater detail.
PTEN (Phosphatase and tensin homologue) was originally identiﬁed
as a tumor suppressor gene frequently lost on chromosome 10q23
[35,36]. PTEN functions as a lipid phosphatase, dephosphorylating the
3′ position of phosphoinositide 3,4,5-triphosphate (PIP3) that becomes
activated through the PI3K (phosphatidylinositol-3-kinase) and in turn
triggers stimulation of AKT (also known as Protein kinase B) [37]. More-
over, PTEN inhibits the activation of ERK signaling pathways by its
protein tyrosine phosphatase activity, thereby negatively regulating
cell cycling, proliferation, focal adhesion, and cell migration [38].
Recently,we reported that thedownregulation of PTENgene expression
by the promoter hypermethylation of PTEN was observed in activated
HSC and the liver tissues from CCl4-treated rats. The inhibition of
DNMT1 by DNA methylation inhibitor 5-azadC or silencing DNMT1
gene decreased aberrant hypermethylation of the PTEN gene promoter
and prevented the loss of PTEN expression, followed the repression of
both ERK and AKT pathway in HSC-T6 cells [39]. These suggests that
PTEN hypermethylation is a central event in liver ﬁbrosis.
RASAL1RasGTPase activating-like protein 1 (RASAL1) gene is located
at chromosome 12q23–24 and is a member of the RAS–GAP family,
which catalyses Ras inactivation by binding to GTP–Ras and catalysing
hydrolysis to GDP–Ras [40,41]. The downregulation of RASAL1 has
been reported inmany tumors, including bladder, liver, gastric, colorec-
tal cancer and multiple cell lines [41–48]. Loss of RASAL1 activity has
been correlated with hyperactive Ras in the colon and hepatocellular
carcinoma lacking oncogenic Ras [43,45].Ohta et al. were able to con-
ﬁrm that ectopic expression of RASAL1 in transfected cells in culture
could promote Ras inactivation, as well as suppression of signaling to
the Ras downstream effector, ERK [45]. A recent study from ourlaboratory observed that treatment of PDGF-induced HSCs with
5-azadC prevents loss of RASAL1 expression that occurs during HSCs
proliferation. In addition, silencing of MeCP2 increased RASAL1 in
both mRNA and protein level in myoﬁbroblasts [49]. These studies
suggest that the expression of RASAL1 mediated by DNA methylation
and MeCP2 may provide molecular mechanisms for HSC activation
and liver ﬁbrosis.
PTCH1: The gene patched1 (PTCH1) is an pivotal developmental
regulator and tumor suppressor gene in vertebrates [50]. In mam-
mals, Sonic hedgehog (Shh) have been identiﬁed and coded for
secreted proteins which bind to multi-pass transmembrane receptors
named PTCH1 [51,52]. The presence of Shh ligands and their binding
to PTCH1 receptor or mutational inactivation of PTCH1 relieves the
inhibition of Smoothened culminating in the activation of one or
more of glioma-associated oncogene homolog 1 (Gli1) transcription
factors that regulate the expression of downstream targets [53,54].
Methylation of PTCH1 is present in gastric cancers and pediatric
medulloblastomas, however, treatment with 5-azadC increases the
expression of PTCH1 [55,56]. Moreover, we demonstrated that the
loss of PTCH1 expression was observed in CCL4-treated liver in rats
and TGF-β1-induced HSCs, however, 5-azadC treatment prevented
loss of PTCH1 expression that occurred during HSCs activation. An
aberrant methylation occurred in PTCH1 gene promoter contributes
to the increase in Gli1 and Smad3 activity during HSC activation
[57]. These results suggest that PTCH1 hypermethylation as a mecha-
nism of HSC activation and liver ﬁbrosis.
PPARγ: Transcription factor peroxisome proliferator-activated
receptor-γ (PPARγ) has four isoforms, γ1, γ2, γ3 and γ4, which
differ only in their N-terminal sequence and have similar transcrip-
tional activities [58]. PPARγ, a ligand-activated transcriptional factor
that belongs to the nuclear hormone receptor superfamily, is predom-
inantly present in liver and adipose tissue [59]. There are increasing
evidences that the decrease of PPARγ expression was observed
during HSC activation, however overexpression of PPARγ or PPARγ
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duced collagen secretion both in vitro and in vivo [60–62]. Moreover,
adipogenic transcriptional regulation of PPARγ by epigenetic modiﬁ-
cation occurred during HSC activation, because silencing of MeCP2 or
5-azadC treatment blocked HSC myoﬁbroblastic transdifferentiation
and prevented the diminished PPARγ expression in HSCs [23].The
observations indicate that epigenetic modiﬁcations of PPARγ play in
a pivotal role in liver ﬁbrosis.
NFκB: Nuclear factor κB (NFκB) originally described as a nuclear
transcription factor required for immunoglobulin kappa light chain
transcription in B lymphocytes that bound to κB target DNA sites [63].
Since then it has been demonstrated that NF-κB is constitutively
expressed in all cell types and regulates transcription of many cellular
activation events critical for development, proper control of cell growth
and proliferation, the immune response, control of apoptosis and
survival, and stress responses to a variety of noxious stimuli [64,65].
Aberrant NFκB activity can lead to constitutive overproduction of
proinﬂammatory cytokines, which is associatedwith a variety of chron-
ic inﬂammatory disorders [66,67]. Moreover, constitutive activation of
NFκB has been observed in patients with liver diseases such as hepatitis
B, hepatitis C, or hepatocellular carcinoma [68]. Speciﬁc NFκB inhibitor
proteins, known as IκBs, control NFκB signaling [69]. The inhibition of
NFκB activity resulted in hepatic stellate cell apoptosis and decreased
ﬁbrogenesis. In contrast, NFκB activity is increased by the repression
of IκB, which promotes stellate cell survival and therefore increased
ﬁbrosis [70]. This ﬁnding has been exploited by demonstrating
that 5-azadC prevented loss of IκB expression that occurs during
transdifferentiation to allow acquisition of proinﬂammatory character-
istics. Moreover, ChIP analysis revealed IκB promoter is associated with
transcriptionally repressed chromatin that converts to an active state
with 5-azadC treatment. Interestingly, siRNA knockdown of MeCP2
elevated IκB a promoter activity, mRNA and protein expression in
myoﬁbroblasts. Further study demonstrated that MeCP2 interacts
with IκB a promoter via a methyl-CpG-dependent mechanism and
recruitment into a CBF1 corepression complex [23].
5. Erasure of aberrant DNA methylation in liver ﬁbrosis
Since aberrant hypermethylation of speciﬁc gene contributes to
HSC activation and ﬁbrogenesis, erasing pathological methylation
seems to be an attractive therapeutic strategy. Therefore, utilization
of endogenous-de-methylating mechanisms may prove to be even
more attractive in the future to possibly convert the ﬁbrogenic pro-
gram to physiologic repair and possibly facilitate regeneration of
chronic liver disease. Recent studies suggest that there might be
multiple pathways or mechanisms by which 5hmC and Tet family
proteins regulate DNA methylation dynamics and gene transcription
[71]. The Ten-Eleven-Translocation (TET) proteins TET1, TET2 and
TET3, known as the mammalian homologous of the trypanosome
proteins JBP1 and JBP2, generate hydroxyl-methyl-cytosine (5hmC)
through addition of a hydroxyl group onto the methyl-group of 5mC
[72,73]. In addition, TET proteins were reported to be able to further
convert 5hmC to 5-formylcytosine and 5-carboxylcytosine, which
can subsequently be recognized and excised by thymine DNA
glycosylase (TDG) in vitro and in vivo [74–76]. Subsequent repair of
the resulting abasic site by base excision repair (BER) can regenerate
an unmethylated cytosine [77]. Recent studies suggest that TET
proteins, important contributors in DNA demethylation process,
have essential roles in neuro development and aging and are involved
in human cancers [78,79]. A recent study have demonstrated that the
decrease of PTCH1 gene expression due to increase CpG methylation
after Tet1 depletion in Mouse Embryonic Stem Cells [80]. Moreover,
the decrease of PTCH1 gene by DNA methylation was observed in
activated HSC [57]. These results suggest that the decrease of PTCH1
by DNA methylation may be dependent on the loss of TET1 in liver
ﬁbrosis. In summary, CpG island promoter methylation can be erasedin principle, an involvement of endogenous demethylating mecha-
nisms in liver repair and liver ﬁbrosis has not yet been explored but
deserves further consideration.
6. Overview of miRNA
miRNA is a widely studied small, non-coding and single-strand RNA
of 19–22 nucleotides [81]. Genes encoding miRNAs are transcribed as
primary miRNA transcripts (pri-miRNAs) by the polymerase activity
of Pol II [82,83]. Pri-miRNAs are processed by the “micro-processor
complex”; a Class 2 RNase III endonuclease (Drosha) to produce stem-
loop-structured miRNA precursors (pre-miRNAs) [84,85]. Pre-miRNAs
are exported to the cytoplasm, where Dicer generates ~21 nucleotide
double-stranded RNA intermediates [86]. Such double-stranded RNAs
are processed further, and one strand, the mature miRNA, interacts
with Argonaute (Ago) proteins to form miRNA–protein complexes
(miRNPs) [87,88]. miRNA is found to result in translational repression
of protein-coding genes via sequence-speciﬁc binding of its seed region
to the untranslated region (UTR) of its target protein-coding genes
[81,89]. miRNAs are involved in post-translational gene silencing by
controlling mRNA translation into proteins, and hence participate in
the regulation of various cellular functions, including development,
apoptosis, proliferation and differentiation [90–93]. miRNAs can also
be divided into tumor suppressive and oncogenic miRNA, depending
onwhether they target conventional tumour suppressors or oncogenes,
respectively [94]. mRNA degradation occurs occasionally in animals
when the miRNA guide template binds to the mRNA transcript and
activate the RNase activity of its associated Ago protein. Translational
repression is found more frequently in animals, and arises from the
miRNA guide molecule in a RNA-induced silencing complex binding
imperfectly with a sequence in the 3′-UTR of a target mRNA [95].
In addition to the direct binding of miRNAs to their target genes,
miRNAs can regulate gene expression by binding to RNA-binding pro-
teins (RBPs) that usually act as transcriptional activators or repressors
[96]. MiRNAs is identiﬁed to bind protein domains that usually recog-
nize and bind RNA secondary structures, acting as decoys and there-
fore preventing the positioning of the RBPs and abrogating their
function [97,98].
7. The crosstalk between DNA methylation and microRNAs in
liver ﬁbrosis
7.1. miRNAs target DNMTs, MeCP2 in liver ﬁbrosis
There are accumulating data that some miRNAs target, directly or
indirectly, effectors of the epigenetic machinery such as DNMTs and
MeCP2 [99–102] (Fig. 2). DNMTs targeted directly by some miRNAs
is conﬁrmed ﬁrstly in cancer research. For example, one published
study showed that in lung cancer, the miR-29 family directly targets
DNMT3A and 3B, thereby leading to down-regulation of these
genes, reduction of global DNA methylation, and reexpression of the
DNA hypermethylated and silenced tumor suppressor genes FHIT
and WWOX [100]. In addition, several groups have shown that that
some miRNAs target, indirectly, DNMTs. Enforced expression of
miR-29b in acute myeloid leukemia cells resulted in marked reduc-
tion of the expression of DNMT1, DNMT3A, and DNMT3B at both
RNA and protein levels. Although down-regulation of DNMT3A and
DNMT3B was the result of a direct interaction of miR-29b with the
3′ untranslated regions of these genes, no predicted miR-29b interac-
tion sites were found in the DNMT1 3′ untranslated regions. Further
experiments revealed that miR-29b down-regulates DNMT1 indirect-
ly by targeting Sp1, a transactivator of the DNMT1 gene [103]. These
results are also in agreement with the work of Qin H et al. who
reported miR-29b negatively regulates DNMT1 expression by
targeting sp1 in T cells. The overexpression of miR-29b contributes
to the reduction of DNMT1 levels and thereby DNA hypomethylation
miR29
DNMT1DNMT3A/3B
miR21
sp1 RASGRP1
DNMT1PTENWWOXFHIT
leukemialupusLiver fibrosisLung cancer
Fig. 2. MiRNAs repressed gene expression by targeting, directly or indirectly, DNMTs and MeCP2 in various diseases.
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in CD4+ T cells from both patients with lupus and lupus-prone
MRL/lpr mice, which promote cell hypomethylation by repressing
DNMT1 expression. Further experiments revealed that miR-21 indi-
rectly downregulated DNMT1 expression by targeting an important
autoimmune gene, RASGRP1, which mediated the Ras-MAPK path-
way upstream of DNMT1 [105].
In the pathogenesis of liver ﬁbrosis, an increasing evidence suggest
that miRNAs are involved in the control of DNA methylation by
targeting the DNA methylation machinery. MiR-29 was signiﬁcantly
down-regulated in livers of CCl4-treated mice as well as in mice that
underwent bile duct ligation and transition of HSC into myoﬁbroblastic,
however transfection of a miR-29b precursor markedly attenuated the
expression of Col1a1 and Col1a2 mRNAs and additionally blunted the
increased expression of α-SMA, DDR2, FN1, ITGB1, and PDGFR-β,
which are key genes involved in the activation of HSCs [106–108].
Recently, we have demonstrated that DNMT1 was upregulated in
the ﬁbrotic livers from CCl4-treated livers and in cultured HSCs after ac-
tivation. Knockdown of DNMT1 by RNAi inhibited HSC activation and
proliferation, and reversed the methylation of PTEN gene promoter
and subsequently restored PTEN gene expression [39]. These studies
suggest that the loss of miR-29 may contribute to the activation of
DNMT1 during liver ﬁbrosis. Nevertheless, additional mechanisms are
necessary to attain such an effect remains to be fully elucidated.
7.2. Aberrant methylation of miRNAs in liver ﬁbrosis
Downregulation of miRNA expression in cancers may be con-
trolled by diverse mechanisms, ranging from epigenetic modiﬁcation,
gene mutation or copy number loss to defective miRNA biogenesis or
post-transcriptional processing [109].
DNAhypermethylation of CpG siteswithin CpG islands is knownas an
epigenetic aberration resulting in silencing of tumor-suppressive miRNA
(TS-miRNA) in cancer cells, in the samemanner as that of many classical
tumor-suppressor gene (TSG) [110,111]. Furthermore, downregulation
ofmiRNA expression could be reverted by treatmentwith demethylating
agents such as 5-azadC, suggesting that expression of these miRNAs
was regulated by DNA hypermethylation [112]. Although the genomic
distances between the 5′-end of intergenic miRNA genes or host genes
harboring intronicmiRNA and their proximal CpG islands vary, these dis-
tances might provide more important information for the understanding
of epigenetic dysregulation of tumor-suppressor miRNA genes by pro-
moter DNA methylation [113]. Therefore, a better understanding ofepigenetic inactivation of speciﬁc tumor-suppressor miRNA genes is
essential for the treatment in liver ﬁbrosis.
The expression of miR-146a was downregulated in HSC in response
to TGF-β1 stimulation and CCL4-treated rat liver [114]. In vitro,
miR-146a overexpression in NKTL cell lines, SNK6 and YT, inhibited
NFκB activity, suppressed cell proliferation, induced apoptosis, and
enhanced chemosensitivity. TNF receptor-associated factor 6, a target
of miR-146a and a known NFκB activator, was downregulated by
miR-146a in SNK6 and YT cells [115]. In addition, The HSC transfected
with miR-146a mimics exhibited attendated TGF-β1-induced α-SMA
expression and the proliferation of HSC and increased HSC apoptosis
[114]. Promoter methylation of miR-146a gene was observed in SNK6
and YT cells, as well as in NKTL tissues with low miR-146a expression
and miR-146a expression was induced by the conversion of methyla-
tion status with a demethylating agent in SNK6 and YT cells [115]. In
addition, the promoter-associated CpG island of the miR-194 cluster
was hypermethylated, and hence, upon hypomethylation treatment,
the miR-194 cluster could be re-expressed in human myeloma cell
lines [116]. Expression of miRNA-194 was reduced in HSC isolated
from ﬁbrotic rats compared with sham-operated animals. Moreover,
miRNA-194 overexpressed in LX-2 cells, and their ability to inhibit cell
proliferation, the expression of α-SMA, a marker for activation, and
collagen type I, a marker for ECM secretion, was determined [24].
These studies suggest that the downregulation of some miRNAs may
be attributed to promoter methylation of miRNAs in liver ﬁbrosis.
In hematological cancers, Chim et al. studied the methylation status
of the miR-34a in a broad spectrum of primary samples, consisting of
AML, chronic myeloid leukemia (CML), acute lymphoblastic leukemia
(ALL), chronic lymphocytic leukemia (CLL), MM, non-Hodgkin's
lymphoma (NHL) and Philadelphia chromosome-negative (Ph−) mye-
loproliferative diseases (MDS). Both of these studies showed that the
promoter-associated CpG island of the miR-34a was unmethylated in
normal controls but aberrantly methylated in 50% of the hematological
cancer cell lines, including human myeloma cell lines (HMCLs). Treat-
ment with 5-aza-2′-deoxycytidine led to demethylation of the miR-34a
promoter and consequent re-expression of the pri-miR-34a transcript
in cells homozygouslymethylated for themiR-34a [117,118]. In addition,
treatment of normal human hepatocytes (N-Heps) and cholangiocytes
human intrahepatic biliary epithelial cells (HiBECs) with ethanol and
lipopolysaccharide induced a signiﬁcant increase of miR-34a expression.
Overexpression ofmiR-34a decreased ethanol-induced apoptosis in both
N-Heps and HiBECs. The 5′-promoter region of miR-34a was noted to be
embedded within a CpG island, the expression level of miR-34a was
1842 E.-B. Bian et al. / Cellular Signalling 25 (2013) 1837–1844signiﬁcantly increased after demethylation treatment in N-Heps and
HiBECs. Furthermore, modulation of miR-34a also altered expression of
matrix metalloproteases 1 and 2, the mediators involved in hepatic
remodeling during alcoholic liver ﬁbrosis [119].7.3. The interaction DNA methylation with microRNAs
More and more evidences showed that a functional crosstalk
between DNAmethylation and miRNAs was involved in cancer devel-
opment. For example, Xiang Y et al. demonstrated that miR-152 was
signiﬁcantly downregulated in the cisplatin-resistant ovarian cell
lines, whereas the overexpression of miR-152 increased cisplatin
sensitivity of cisplatin-resistant ovarian cell lines by inhibiting prolifer-
ation and promoting apoptosis, then we further conﬁrmed that these
miRNAs functioned through suppressingDNMT1 directly [120]. In addi-
tion, the expression of miR-152 was frequently down-regulated in
HBV-related HCC tissues in comparison with adjacent noncancerous
hepatic tissues and was inversely correlated to DNMT1 expression in
HBV-related HCCs. The forced expression of miR-152 in liver cell lines
resulted in a marked reduction of DNMT1 expression by directly
targeting the 3′ untranslated regions of DNMT1. This in turn led to a
decrease in global DNA methylation, whereas inhibition of miR-152
caused global DNA hypermethylation and increased the methylation
levels of two tumor suppressor genes, glutathione S-transferase pi 1
(GSTP1) and E-cadherin 1 (CDH1) [121]. These results suggest that the
interaction of miRNAs with DNMTs regulate gene expression. Interest-
ingly, the expression of miR-152 was speciﬁcally downregulated in
NiS-transformed cells via promoter DNA hypermethylation, whereas
ectopic expression of miR-152 caused a marked reduction of DNMT1
expression, which led to a signiﬁcant decrease of cell growth in
NiS-transformed cells. Further experiments revealed that miR-152
directly downregulated DNMT1 expression by targeting the 3′
untranslated regions of its transcript. Treatment of DNMT inhibitor,
5-azadC, or depletion of DNMT1 led to increased miR-152 expression
by reversion of promoter hypermethylation, DNMT1 andMeCP2 binding
to miR-152 promoter in NiS-transformed cells. Moreover, inhibition of
miR-152 expression could increase DNMT1 expression and result in an
increase in DNA methylation, DNMT1 and MeCP2 binding to miR-152
promoter, which signiﬁcantly increased cell growth in 16HBE cellsOvarian
DNMT1
MeCP2
PPAR
Liver 
fibrosis
Preconditioning
ischemia
NiS-transformed
16HBE cell
miR152
Fig. 3. Overview of a functional crosstalk between miRNAs and DNA[122]. These results suggest that a functional crosstalk between miRNAs
and DNA methylation is involved in controlling gene expression.
Decreased expression of miR-132 by promoter hypermethylation
was conﬁrmed pancreatic cancerous tissues and in PANC1 and
SW1990 cells. Moreover, cancerous tissues showed signiﬁcantly
lower Sp1-binding afﬁnity to the miR-132 promoter, relative to
non-tumor samples. Proliferation and colony formation of pancreatic
cancer cells were suppressed in cells transfected with miR-132
mimics and enhanced in cells transfected with miR-132 inhibitor by
negatively regulating the Akt-signaling pathway [123]. Moreover, a
recent study showed that a rapid increase in MeCP2 protein associat-
ed with downregulation of miR-132 was induced in preconditioning
ischemia [124]. Block of miR132-mediated repression increased
MeCP2 and brain-derived neurotrophic factor (BDNF) levels in
cultured rat neurons and the loss of MeCP2 reduced BDNF and
miR132 levels in vivo [101]. This feedback loop may provide new
and profound insights in the interaction of MeCP2 with miRNAs.
Intrauterine growth restriction (IUGR) would in rats alter the levels
of MeCP2 mRNA and protein as well as miR132 and that this will be as-
sociated with changes in PPARγmRNA levels, MeCP2 occupancy at the
PPARγ promoters, and PPARγH3K9Me3 [101]. Transcriptional silencing
of PPARγ gene is required for conversion of HSC into myoﬁbroblasts,
whereas forced over-expression of PPARγ in hepatic myoﬁbroblasts
leads to reversion of transdifferentiation, with down-regulation of
type I collagen, loss of proliferation and reacquisition of their adipogenic
characteristics [60,62]. 5-azadC prevented loss of PPARγ expression that
occurs during transdifferentiation to allow acquisition of proﬁbrogenic
characteristics. Interestingly, MeCP2 is recruited to the 5′ end of
PPARγ, where it promotes methylation by H3K9 and recruits the tran-
scription repressor HP1α during liver ﬁbrosis. Loss of miR132 expres-
sion in myoﬁbroblasts during liver injury was conﬁrmed in HSC
isolated from BDL- and CCl4-injured rat livers, however transfection of
miR132 diminished the expression of MeCP2 protein. This treatment
was also accompanied by increased PPARγ expression [22,23]. These re-
sults suggest that a functional crosstalk between miRNAs and MeCP2
via a double-negative feedback loop is involved in the regulation of
gene expression in liver ﬁbrosis.
In summary, a functional crosstalk between miRNAs and DNA
methylation via a double-negative feedback loop is involved in con-
trolling gene expression (Fig. 3).DNA 
methylationmiR132
CDCH1
GSTP1
HCC
AKT Pancreatic
cancer
methylation is involved in the regulation of gene expression.
1843E.-B. Bian et al. / Cellular Signalling 25 (2013) 1837–18448. Conclusion and prospective
In summary, current data on DNA methylation of speciﬁc gene in
liver ﬁbrosis focus on the loss of tumor-suppressor genes due to promot-
er DNA hypermethylation. Epigenetic inactivation of these TGS is
involved in the pathogenesis and progression of liverﬁbrosis. In addition,
epigenetic silencing of miRNAs by promoter hypermethylation is in-
volved in the regulation of key pathways involved in liver ﬁbrosis. There-
fore, the use of epigenetic drugs was able to induce re-expression of
these TGS and miRNAs could provide a therapeutic advantage for these
patients. Indeed, DNA methylation can be reversed by demethylating
agents 5-azacytidine or decitabine, and therapeutic beneﬁts have been
demonstrated in patients with myelodysplastic syndrome [125]. More-
over, these data also suggest the potential use of tumor-suppressor
miRNAmimics as a liverﬁbrosis therapy in tumors lacking certain critical
tumor-suppressor miRNAs.
Moreover, in this review, we, in particular, emphasize the role of the
interaction of miRNA with DNA methylation in the mechanism of
disease occurs, since epigenetic dysregulation of tumor-suppressor
miRNA genes are found to be due to promoter DNA methylation and
miRNAs can target, directly or indirectly, MeCP2 and DNMTs in speciﬁc
condition. We foresee that the study of the crosstalk between miRNAs
and DNA methylation and the complex pattern of the epigenetic
networks may result in novel hypotheses about pathogenesis liver
ﬁbrosis and may offer a new promise for the treatment of liver ﬁbrosis.
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